AI generated summary. Current AI models can provide useful
summaries for non-experts, but may be inaccurate and have limited ability to
analyze larger context such as the entire evidence base for
Multiple compounds in Nigella sativa were identified that have high binding affinity to the spike protein of SARS-CoV-2 and are promising candidates for the development of new COVID-19 treatments.
- COVID-19 is a respiratory illness caused by the novel coronavirus SARS-CoV-2.
- The spike protein of SARS-CoV-2 is essential for the virus to attach to and enter host cells.
- Nigella sativa (black seed) is a plant that has been used in traditional medicine for centuries.
- The authors of this study used in silico methods to screen N. sativa for compounds that could inhibit the spike protein of SARS-CoV-2.
- They identified several compounds that had high binding affinity to the spike protein and could potentially inhibit its function.
- These compounds were then compared to clinically approved drugs for COVID-19, and they found that some of the N. sativa compounds had similar or even greater binding affinity than the approved drugs.
- The authors concluded that N. sativa could be a potential source of new drugs for the treatment of COVID-19.
The authors of this study provide promising evidence that N. sativa could be a source of new drugs for the treatment of COVID-19.
Computational Prediction of Nigella sativa Compounds as Potential Drug Agents for Targeting Spike Protein of SARS-CoV-2
Pakistan BioMedical Journal, doi:10.54393/pbmj.v6i3.853
COVID-19 pandemic is caused by the novel coronavirus SARS-CoV-2, which is a member of the Coronaviridae family in the Nidovirales order . The virus was rst identi ed in Wuhan, China in late 2019 and has since spread globally, leading to widespread illness and death . Coronaviruses are responsible for a range of diseases, including respiratory, digestive, enteric, and neurological disorders . The highly transmissible nature of the virus has resulted in its spread to 216 countries worldwide . As of the latest reported gures, there have been 759,408,703 con rmed cases of 866,434 deaths
C o n i c t s o f I n t e r e s t The authors declare no con ict of interest.
S o u r c e o f F u n d i n g The authors received no nancial support for the research, authorship and/or publication of this article.
Coutard, Valle, De Lamballerie, Canard, Seidah et al., The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade, Antiviral
Cvetković, Nikolić, Nenadić, Öcal, Noji et al., Preparedness and preventive behaviors for a pandemic disaster caused by COVID-19 in Serbia, International Journal of Environmental Research and Public Health, doi:10.3390/erph17114124
E F E R E N C E S Gorbalenya, Baker, Baric, De Groot, Drosten et al., The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2, Nature Microbiology, doi:10.1038/s41564-020-0695-z
Kamble, Daulatabad, John, John, Synopsis of symptoms of COVID-19 during second wave of the pandemic in India, Hormone Molecular Biology and Clinical Investigation, doi:10.1515/hmbci-2021-0043
Ng, Li, Chua, Chaw, Zhao et al., Evaluation of the effectiveness of surveillance and containment measures for the rst 100 patients with COVID-19 in Singapore-January 2-February 29, Morbidity and Mortality Weekly Report, doi:10.15585/mmwr.mm6911e1
Yin, Li, Ye, Ruan, Liang et al., Molecular docking and dynamic simulation of Olea europaea and Curcuma Longa compounds as potential drug agents for targeting Main-Protease of SARS-nCoV2, doi:10.1016/j.csbj.2022.01